sinusitis

Moxifloxacin hydrochloride (BAY12-8039 HCl) is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice.

Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally administered, broad-spectrum penicillin antibiotic used for treating mild to moderate infections caused by susceptible gram-positive organisms.

Telithromycin is a semisynthetic 14-membered macrolide antibiotic and erythromycin derivative that binds to the 50S subunit of the 70S bacterial ribosome, inhibits bacterial protein synthesis, and exhibits antimicrobial activity against a wide range of gram-positive and gram-negative bacteria for the treatment of mild to moderate respiratory infections.

(R)-MMP-408 is an isomer of MMP-408, which is an effective MMP-12 inhibitor with an IC₅₀ of 2 nM against human MMP-12. (R)-MMP 408 can influence the epithelial-mesenchymal transition (EMT) process in nasal epithelial cells and is suitable for use in research on chronic obstructive pulmonary disease (COPD) and chronic sinusitis.

Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is a

Decarboxy Moxifloxacin is a decarboxylated compound of moxifloxacin. Moxifloxacin is an oral active 8-methoxyquinolone antibiotic used in acute bacterial sinusitis, chronic bronchitis, acute bacterial deterioration, and community-acquired pneumonia.

Fenspiride hydrochloride (Decaspiride) , an oxazolidinone spiro compound, is a drug used in the therapy of certain respiratory diseases. It is approved for use in Russia for the therapy of chronic and acute inflammatory diseases of ENT organs and the respiratory tract (like sinusitis, tracheobronchitis, otitis, laryngitis, and rhinopharyngitis), and for maintenance therapy of asthma.

Eucalyptol, a natural monoterpenoid and cyclic ether found in eucalyptus species, effectively controls excessive airway mucus secretion and asthma by inhibiting pro-inflammatory cytokines. It serves as an efficacious treatment for non-purulent sinusitis, reducing inflammation and pain when applied topically, and demonstrating leukemic cell-killing capabilities in vitro.

Cefdinir is an advanced broad-spectrum cephalosporin antibacterial compound approved for treating community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, acute bacterial otitis media, and uncomplicated skin and skin structure infections in both adult and pediatric patients.

Moxifloxacin-D is the hydrochloride salt form of deuterium-labeled Moxifloxacin (Moxifloxacin). This compound acts as an orally effective antibacterial agent and is utilized in research concerning acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and infectious pneumonia.

Tetranor-Misoprostol is a derivative of Moxifloxacin and an active metabolite of the prostaglandin E1 analogue. Moxifloxacin is an 8-methoxyquinolone antibacterial antibiotic used in the study of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and pneumonia.

Moxifloxacin N-sulfate is a metabolite of moxifloxacin . Moxifloxacin is a fluoroquinolone antibiotic. Formulations containing moxifloxacin have been used in the treatment of bacterial infections, including sinusitis, chronic bronchitis, and pneumonia.

Penicillin V (Phenoxymethylpenicillin) is an effective, orally-administered antibiotic with activity against Streptococci, Clostridium difficile, and Staphylococcus aureus. It holds potential for research into treatments for otitis, sinusitis, pharyngitis, and tonsillitis [1] [2] [3] [4].

Etokimab (ANB-020) is a humanised monoclonal antibody targeting IL-33, capable of inhibiting IL-33-induced neutrophil migration, and is being studied for atopic dermatitis, asthma, and sinusitis.

IDR 1002, an innate defense regulator peptide, effectively diminishes bacterial load and mitigates inflammatory responses in murine models of sinusitis and acute bacterial lung infections. It suppresses LPS-induced activation of NF-κB and COX-2 while promoting the phosphorylation and activation of p38, ERK1/2, MSK1, and CREB.

Cefpodoxime proxetil-D3 is a deuterated compound of Cefpodoxime proxetil. Cefpodoxime proxetil (T4998) has a CAS number of 87239-81-4. Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil (T4998) is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.

Moxifloxacin-13C,D3 hydrochloride is the 13C labeled variant of Moxifloxacin hydrochloride (TMSM-1673). Moxifloxacin is an orally effective 8-methoxyquinolone compound with antibacterial properties, used in the study of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and infectious pneumonia.

Moxifloxacin N-sulfate disodium is an anionic sulfonate derivative of Moxifloxacin. Moxifloxacin is an 8-methoxyquinolone antibacterial antibiotic, used in studies of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and infectious pneumonia.

(Rac)-Moxifloxacin ((Rac)-BAY 12-8039 free base) is an isomer of Moxifloxacin Hydrochloride. Moxifloxacin Hydrochloride (BAY 12-8039) is an orally effective 8-methoxyquinolone antibacterial agent used in studies on acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and infectious pneumonia.